|Strain Name||C57BL/6-Lag3tm1(hLAG3)/Bcgen||Common Name||B-hLAG3 mice|
|Catalog number (Males)||BCM046M||Catalog number (Females)||BCM046F|
|Related Genes||Lag3 (lymphocyte-activation gene 3)|
LAG3 (Lymphocyte activation gene 3, CD223) is a lymphocyte activation gene and a member of the Ig family. It is mainly expressed in activated T cells, NK cells, B cells and plasmacytoid DCs. LAG3 is a negative regulator of immunity and mainly binds to MHC class Ⅱ molecules to regulate the function of dendritic cells. The expression of LAG3 is associated with the negative immunoregulatory function of specific T cells. Inhibition of LAG3 function enhances the anti-tumor effect of specific CD8+ T cells, therefore LAG3 is a potential target for tumor immunotherapy.
Protein expression analysis
Fig 1. Splenocytes from both wild type (WT) C57BL/6 and B-hLAG3 homozygous mice were analyzed by flow cytometry.
Mouse LAG3+ T cells were detected in the WT mice, while human LAG3+ T cells were detected in the B-hLAG3 homozygous mice. Mouse LAG3+ T cells were also detected in the B-hLAG3 homozygous mice. The reason maybe that the anti-mouse LAG3 antibody cross-reacts with human LAG3.
LAG3 Abs efficacy evaluation
Fig 2. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hLAG3 mice. Mice were divided into control and treatment groups (n = 5) when the tumor volume was about 100 mm3. Anti-human LAG3 antibody Ab2, but not Ab1, significantly inhibited tumor growth in the homozygous B-hLAG3 mice, suggesting that B-hLAG3 mouse model is a powerful tool for human LAG3 antibody efficacy studies in vivo. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.